B. Riley assumed coverage on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a research report sent to investors on Friday, The Fly reports. The brokerage issued a buy rating and a $23.00 price target on the stock.
A number of other research analysts have also commented on the company. HC Wainwright reaffirmed a buy rating and set a $30.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, November 7th. BidaskClub lowered Karyopharm Therapeutics from a buy rating to a hold rating in a research report on Saturday, September 29th. ValuEngine lowered Karyopharm Therapeutics from a strong-buy rating to a buy rating in a research report on Thursday, October 11th. Wedbush raised Karyopharm Therapeutics from a neutral rating to an outperform rating and set a $19.00 price target for the company in a research report on Friday, November 9th. Finally, Robert W. Baird reaffirmed a buy rating and set a $25.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, August 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $22.90.
Shares of NASDAQ KPTI traded up $0.84 during midday trading on Friday, reaching $10.40. The company had a trading volume of 872,569 shares, compared to its average volume of 492,985. Karyopharm Therapeutics has a one year low of $9.00 and a one year high of $21.71.
In other news, major shareholder Ltd Chione sold 164,800 shares of the stock in a transaction that occurred on Thursday, September 6th. The stock was sold at an average price of $21.05, for a total value of $3,469,040.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael Kauffman sold 9,600 shares of the stock in a transaction that occurred on Monday, November 26th. The stock was sold at an average price of $11.00, for a total value of $105,600.00. Following the completion of the transaction, the chief executive officer now directly owns 521,743 shares of the company’s stock, valued at approximately $5,739,173. The disclosure for this sale can be found here. Insiders have sold a total of 493,768 shares of company stock valued at $9,926,611 in the last ninety days. 13.26% of the stock is currently owned by corporate insiders.
Large investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new position in shares of Karyopharm Therapeutics in the 3rd quarter worth approximately $195,000. Verition Fund Management LLC purchased a new stake in shares of Karyopharm Therapeutics in the 3rd quarter worth approximately $242,000. Fox Run Management L.L.C. purchased a new stake in shares of Karyopharm Therapeutics in the 3rd quarter worth approximately $266,000. Metropolitan Life Insurance Co. NY grew its stake in shares of Karyopharm Therapeutics by 38.9% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 16,275 shares of the company’s stock worth $277,000 after buying an additional 4,556 shares during the last quarter. Finally, Voya Investment Management LLC grew its stake in shares of Karyopharm Therapeutics by 24.3% in the 2nd quarter. Voya Investment Management LLC now owns 18,661 shares of the company’s stock worth $317,000 after buying an additional 3,653 shares during the last quarter. 72.03% of the stock is owned by hedge funds and other institutional investors.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Featured Story: Risk Tolerance
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.